{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-021339","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.140870+00:00","generated_at":"2026-06-01T01:00:19.243248+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Genprex begins treating patients in two new lung cancer trials, continues third","bullets":["Opened enrollment and began treating patients in two new lung cancer clinical trials in 2024.","Continues treating patients in a third lung cancer clinical trial.","Partnered with community-based oncology practices to broaden clinical study reach.","Expanded preclinical programs into new indications; presented positive data at major cancer conference.","Strengthened global IP estate for lead drug candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-021339","json":"https://secwatch.observer/filing/0001437749-24-021339.json","markdown":"https://secwatch.observer/filing/0001437749-24-021339.md","text":"https://secwatch.observer/filing/0001437749-24-021339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924021339/0001437749-24-021339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924021339/gnpx20240507_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:00:19.243248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}